Postmarketing Hepatic Monitoring for Pazopanib Using Observational Databases

Trial Profile

Postmarketing Hepatic Monitoring for Pazopanib Using Observational Databases

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Pazopanib (Primary) ; Bevacizumab; Sorafenib; Sunitinib
  • Indications Renal cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Feb 2013 Planned number of patients changed (1) added as reported by ClinicalTrials.gov record.
    • 21 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top